Asha Therapeutics is a life sciences company at the forefront of a new era of precision drug design, leveraging the power of its PRISM™ technology to custom design de novo compounds to create curative therapeutics for diseases with high unmet medical need across multiple clinical areas including neurology, oncology, and infectious disease. Asha's lead therapeutic programs, ASHA-624 and ASHA-091 with indications in Amyotrophic Lateral Sclerosis, Parkinson's Disease and ME/CFS and Long Covid respectively, are expected to enter clinical trials by mid-2024 and are disease modifying therapeutics.